Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Major response to imatinib mesylate in KIT-mutated melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2008

Hodi F Stephen, Friedlander Philip, Corless Christopher L, Heinrich Michael C, Mac Rae Suzanne, Kruse Andrea, Jagannathan Jyothi, Van den Abbeele Annick D, Velazquez Elsa F, Demetri George D, Fisher David E

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Imatinib Mesylate
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Rectal Neoplasms

Source

Identifiers

PMID: 18421059
DOI: 10.1200/JCO.2007.14.0707

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Major response to imatinib mesylate in KIT-mutated melanoma.PMID 18421059Read ↗

KIT mutations in a series of melanomas and their impact on treatment with imatinib.Semantic proximity Read ↗

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.Semantic proximity Read ↗

V559A and N822I double KIT mutant melanoma with predictable response to imatinib?Semantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

Imatinib targeting of KIT-mutant oncoprotein in melanoma.Semantic proximity Read ↗

Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).Semantic proximity Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.Semantic proximity Read ↗

JAK-ing up the Response to KIT Inhibition.Semantic proximity Read ↗

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).Semantic proximity Read ↗

Complete response in a melanoma patient treated with imatinib.Semantic proximity Read ↗

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.